Fusion Antibodies inched 5.5% higher to 47.5p following the launch of a new commercial service, named Mammalian Display, from its R&D programme.
The specialist pre-clinical antibody discovery, engineering and supply group said in a statement that the service is the first from the company’s OptiMAL programme, which Fusion has commercialised and is now offering to clients.
Fusion said the service is especially suited to companies specialising in the identification of therapeutic antibodies.
“We are delighted to be able to announce the successful development of the Mammalian Display technology, an output from our OptiMAL research programme,” said chief executive Adrian Kinkaid.